Absence of Epstein-Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria

2004 ◽  
Vol 35 (4) ◽  
pp. 455-459 ◽  
Author(s):  
Marco Herling ◽  
George Z Rassidakis ◽  
Dan Jones ◽  
Annette Schmitt-Graeff ◽  
Andreas H Sarris ◽  
...  
1992 ◽  
Vol 98 (3) ◽  
pp. 312-318 ◽  
Author(s):  
Bettina Borisch ◽  
Kevin C. Gatter ◽  
Andreas Tobler ◽  
L. Theilkäs ◽  
Christopher Bunch ◽  
...  

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Parag Mahale ◽  
Jason Nomburg ◽  
Joo Y. Song ◽  
Mia Steinberg ◽  
Gabriel Starrett ◽  
...  

AbstractSystemic anaplastic large cell lymphoma (ALCL) is a rare CD30-expressing T-cell non-Hodgkin lymphoma. Risk of systemic ALCL is highly increased among immunosuppressed individuals. Because risk of cancers associated with viruses is increased with immunosuppression, we conducted a metagenomic analysis of systemic ALCL to determine whether a known or novel pathogen is associated with this malignancy. Total RNA was extracted and sequenced from formalin-fixed paraffin-embedded tumor specimens from 19 systemic ALCL cases (including one case from an immunosuppressed individual with human immunodeficiency virus infection), 3 Epstein-Barr virus positive diffuse large B-cell lymphomas (DLBCLs) occurring in solid organ transplant recipients (positive controls), and 3 breast cancers (negative controls). We used a pipeline based on the Genome Analysis Toolkit (GATK)-PathSeq algorithm to subtract out human RNA reads and map the remaining RNA reads to microbes. No microbial association with ALCL was identified, but we found Epstein-Barr virus in the DLBCL positive controls and determined the breast cancers to be negative. In conclusion, we did not find a pathogen associated with systemic ALCL, but because we analyzed only one ALCL tumor from an immunosuppressed person, we cannot exclude the possibility that a pathogen is associated with some cases that arise in the setting of immunosuppression.


2004 ◽  
Vol 200 (10) ◽  
pp. 669-679 ◽  
Author(s):  
Samina Noorali ◽  
Shahid Pervez ◽  
Nausheen Yaqoob ◽  
Tariq Moatter ◽  
Muhammad Israr Nasir ◽  
...  

Author(s):  
Xiaohui Zhang ◽  
Jiehao Zhou ◽  
Xin Han ◽  
Endi Wang ◽  
Linsheng Zhang

Context.— In the 2017 revised World Health Organization classification of tumors of hematopoietic and lymphoid tissues, some mature T-cell lymphomas are reclassified and a few new provisional entities are established based on new data from clinical and laboratory studies. T follicular helper cell lymphoma is identified by T follicular helper cell markers. Anaplastic large cell lymphoma, ALK negative, is a better-defined entity based on genetic abnormalities, and breast implant–associated anaplastic large cell lymphoma is recognized as a provisional entity. The gastrointestinal T-cell lymphomas are reclassified, with addition of a new provisional entity, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, characterized by an indolent clinical course. Objective.— To review the diagnostic approaches of reclassified and newly established entities of mature T-cell lymphomas, focusing on significant immunophenotypic features and molecular genetic abnormalities. Relevant new discoveries after the publication of the 2017 World Health Organization classification are included. Data Sources.— Information from the literature most relevant to 2017 World Health Organization revised classification and publications after 2016. Conclusions.— Incorporating clinical, morphologic, and immunophenotypic features usually provides sufficient evidence to reach a preliminary diagnosis of mature T-cell lymphoma. Molecular genetic studies can be very helpful for the final diagnosis and classification, especially in challenging cases. Some molecular genetic features have been found in breast implant–associated anaplastic large cell lymphoma, distinct from anaplastic large cell lymphoma, ALK negative. Immunohistochemical staining of 4 markers may enable further subtyping of peripheral T-cell lymphomas.


Sign in / Sign up

Export Citation Format

Share Document